Roche Holding Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Thomas Schinecker

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	2yrs
Ägande av VD	0.0004%
Ledningens genomsnittliga anställningstid	5.2yrs
Styrelsens genomsnittliga mandatperiod	6.5yrs

Senaste uppdateringar av ledningen

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Analys av ersättningar till VD

Hur har Thomas Schinecker:s ersättning förändrats jämfört med Roche Holding:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Dec 31 2024	n/a	n/a	CHF 8b
Sep 30 2024	n/a	n/a	CHF 9b
Jun 30 2024	n/a	n/a	CHF 11b
Mar 31 2024	n/a	n/a	CHF 11b
Dec 31 2023	n/a	n/a	CHF 11b
Sep 30 2023	n/a	n/a	CHF 11b
Jun 30 2023	n/a	n/a	CHF 11b
Mar 31 2023	n/a	n/a	CHF 12b
Dec 31 2022	CHF 5m	CHF 1m	CHF 12b
Sep 30 2022	n/a	n/a	CHF 14b
Jun 30 2022	n/a	n/a	CHF 15b
Mar 31 2022	n/a	n/a	CHF 14b
Dec 31 2021	CHF 4m	CHF 1m	CHF 14b
Sep 30 2021	n/a	n/a	CHF 14b
Jun 30 2021	n/a	n/a	CHF 14b
Mar 31 2021	n/a	n/a	CHF 14b
Dec 31 2020	CHF 4m	CHF 879k	CHF 14b
Sep 30 2020	n/a	n/a	CHF 14b
Jun 30 2020	n/a	n/a	CHF 13b
Mar 31 2020	n/a	n/a	CHF 13b
Dec 31 2019	CHF 2m	CHF 609k	CHF 13b

Ersättning vs marknad: Otillräckliga data för att fastställa om Thomas s total kompensation är rimlig jämfört med företag av liknande storlek på Swiss marknaden.

Ersättning vs inkomst: Ersättningen för Thomas har ökat med mer än 20 % medan företagets intäkter har minskat med mer än 20 % det senaste året.

VD OCH KONCERNCHEF

Thomas Schinecker (49 yo)

2yrs

Anställning

CHF 5,335,592

Kompensation

Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He is Group Chief Executive Officer of Roche Holding AG and served as its Chief Executive Officer since March 15,...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Severin Schwan	Executive Chairman	12yrs	CHF 11.48m	0.043% CHF 104.7m
Thomas Schinecker	Group Chief Executive Officer	2yrs	CHF 5.34m	0.00045% CHF 1.1m
Alan Hippe	Chief Financial & Information Officer	13.9yrs	CHF 6.05m	0.0063% CHF 15.3m
Bruno Eschli	Head of Investor Relations	no data	inga uppgifter	inga uppgifter
Claudia Bockstiegel	General Counsel	4.9yrs	inga uppgifter	inga uppgifter
Pascale Schmidt	Chief Compliance Officer	5.2yrs	inga uppgifter	inga uppgifter
Barbara Schadler	Head of Group Communications	5.4yrs	inga uppgifter	inga uppgifter
Cristina Wilbur	Chief People Officer	9yrs	CHF 4.25m	0.0020% CHF 4.9m
Nicolas Dunant	Head of Group Media Relations	no data	inga uppgifter	inga uppgifter
Boris Zaitra	Head of Corporate Business Development	no data	inga uppgifter	inga uppgifter
Johannes Clevers	Head of Roche Pharma Research & Early Development	3yrs	CHF 82.50k	inga uppgifter
Cristin Hubbard	Senior Vice President of Immunology	no data	inga uppgifter	inga uppgifter

5.2yrs

Genomsnittlig anställningstid

57yo

Genomsnittlig ålder

Erfaren ledning: ROG s ledningsgrupp är erfaren och erfaren ( 5.2 års genomsnittlig anställning).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Severin Schwan	Executive Chairman	12yrs	CHF 11.48m	0.043% CHF 104.7m
Ulf Schneider	Director	2yrs	inga uppgifter	0.00063% CHF 1.5m
Andre Hoffmann	Independent Vice Chairman	29.2yrs	CHF 400.00k	3.54% CHF 8.6b
Patrick Frost	Independent Non Executive Director	5yrs	CHF 360.00k	0.00025% CHF 607.8k
Richard Lifton	Non-Executive Independent Director	10.2yrs	CHF 346.71k	0% CHF 0
Anita Hauser	Non-Executive Independent Director	8yrs	CHF 336.16k	0.00040% CHF 972.4k
Jorg Duschmale	Non-Executive Independent Director	5yrs	CHF 394.60k	inga uppgifter
Akiko Iwasaki	Director	2yrs	inga uppgifter	inga uppgifter
Claudia Ricarda Suessmuth Dyckerhoff	Non-Executive Independent Director	9yrs	CHF 367.02k	0.00034% CHF 826.6k
Jemilah Mahmood	Independent Non-Executive Director	3yrs	CHF 272.50k	inga uppgifter

6.5yrs

Genomsnittlig anställningstid

57yo

Genomsnittlig ålder

Erfaren styrelse: ROG s styrelse anses vara erfaren ( 6.5 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/05 03:56
Aktiekurs vid dagens slut	2025/03/05 00:00
Intäkter	2024/12/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Roche Holding AG bevakas av 58 analytiker. 17 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research

Roche Holding Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Roche Announces Executive and Committee Changes

Roche Announces Management and Board Committee Changes

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Recent updates

Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Full year 2024 earnings: EPS misses analyst expectations

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Roche Announces Executive and Committee Changes

Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer

Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care

Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology

Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche Holding AG (VTX:ROG) Could Be Riskier Than It Looks

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Analys av ersättningar till VD

VD OCH KONCERNCHEF

Anställning

Kompensation

Ledningsgrupp

Genomsnittlig anställningstid